Ryuhei Sano
Overview
Explore the profile of Ryuhei Sano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sano R, Ryu K, Sasase T, Shinozaki Y, Teoh S, Yamaguchi A, et al.
J Toxicol Sci
. 2023 Nov;
48(11):597-606.
PMID: 37914287
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD). Although current therapeutic strategies for DKD, including sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists, have shown some...
2.
Saigo Y, Sasase T, Uno K, Shinozaki Y, Maekawa T, Sano R, et al.
J Pharmacol Toxicol Methods
. 2022 Jun;
116:107190.
PMID: 35688322
An increasing number of patients worldwide are being diagnosed with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NAFLD/NASH) because of the growing prevalence of obesity and metabolic disorders. The incidence...
3.
Suzuki-Kemuriyama N, Abe A, Uno K, Ogawa S, Watanabe A, Sano R, et al.
Lipids Health Dis
. 2022 Jan;
21(1):2.
PMID: 34996474
No abstract available.
4.
Suzuki-Kemuriyama N, Abe A, Nakane S, Uno K, Ogawa S, Watanabe A, et al.
FEBS Open Bio
. 2021 Aug;
11(11):2950-2965.
PMID: 34390210
Nonalcoholic steatohepatitis (NASH) is often associated with obesity, but some patients develop NASH without obesity. The physiological processes by which nonobese patients develop NASH and cirrhosis have not yet been...
5.
Suzuki-Kemuriyama N, Abe A, Uno K, Ogawa S, Watanabe A, Sano R, et al.
Lipids Health Dis
. 2020 Dec;
19(1):251.
PMID: 33317575
Background: Nonalcoholic steatohepatitis (NASH) is a form of liver disease characterized by steatosis, necroinflammation, and fibrosis, resulting in cirrhosis and cancer. Efforts have focused on reducing the intake of trans...
6.
Sano R, Shinozaki Y, Ohta T
J Diabetes Investig
. 2020 Mar;
11(4):770-782.
PMID: 32196987
Glucose is the most abundant monosaccharide, and an essential source of energy for most living cells. Glucose transport across the cell membrane is mediated by two types of transporters: facilitative...
7.
Maekawa M, Tadaki H, Tomimoto D, Okuma C, Sano R, Ishii Y, et al.
Biol Pharm Bull
. 2019 Nov;
42(11):1906-1912.
PMID: 31685773
Tumor necrosis factor-α (TNF-α) converting enzyme/a disintegrin and metalloproteinase domain-containing protein 17 (TACE/ADAM17) is a key sheddase that releases TNF-α from its inactive precursor and is thought as a new...
8.
Iida T, Ubukata M, Mitani I, Nakagawa Y, Maeda K, Imai H, et al.
Eur J Med Chem
. 2018 Sep;
158:832-852.
PMID: 30248655
SCD1 is a rate-limiting enzyme in the conversion of saturated fatty acids to monounsaturated fatty acids. SCD1 inhibitors have potential effects on obesity, diabetes, acne, and cancer, but the adverse...
9.
Okuma C, Ohta T, Tadaki H, Ishigure T, Sakata S, Taniuchi H, et al.
J Pharmacol Sci
. 2015 Jul;
128(3):150-7.
PMID: 26215699
Aim: Monoacyglycerol acyltransferases (MGATs) are known to play important roles in intestinal TG absorption. In contrast, the role of MGATs in the liver is still unclear. We investigated the effects...
10.
Katsuda Y, Kemmochi Y, Maki M, Sano R, Toriniwa Y, Ishii Y, et al.
J Diabetes Res
. 2014 Sep;
2014:363126.
PMID: 25177706
The Spontaneously Diabetic Torii (SDT) fatty rat is a new model for obese type 2 diabetes. The aim of the present study was to investigate the effect of 1/2 nephrectomy...